Ironwood Pharmaceuticals (IRWD) Liabilities and Shareholders Equity (2010 - 2026)

Ironwood Pharmaceuticals has reported Liabilities and Shareholders Equity for 17 years, with the latest figure at $434.6 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 32.81% year-over-year to $434.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 billion (up 7.33% YoY) and the FY2025 annual result came in at $396.9 million, up 13.11% from the prior year.
• Liabilities and Shareholders Equity grew to $434.6 million in Q1 2026 per IRWD's latest filing, from $396.9 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $1.2 billion in Q1 2023 and troughed at $327.2 million in Q1 2025.
• A 5-year average of $613.3 million and a median of $438.8 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity jumped 80.76% in 2022, then plunged 62.02% in 2024.
• Over 5 years, Liabilities and Shareholders Equity stood at $1.1 billion in 2022, then tumbled by 57.2% to $471.1 million in 2023, then retreated by 25.51% to $350.9 million in 2024, then rose by 13.11% to $396.9 million in 2025, then advanced by 9.49% to $434.6 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $434.6 million, $396.9 million, and $396.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.